Home / Companies / Teva Pharmaceutical Industries Limited / 5 Jun 2025
Teva Pharmaceutical Industries Limited: meeting of 5 Jun 2025
Votes reported on Form N-PX, item by item
86 Form N-PX filers reported votes at the Teva Pharmaceutical Industries Limited meeting of 5 Jun 2025. Their records fall into 5 items below, in ballot order: management items first, then proposals from security holders. Each bar shows how the reporting filers split; it is not the result of the meeting.
foragainstabstain, withhold or otheramber tick: the portion cast against management
Items
DIRECTOR ELECTIONSIssuer
Director elections
5 nominees; 97.9% of reported votes for; one filer withheld from or voted against at least one nominee.
205 vote records from 25 filers. 0 of the 24 filers that marked the item either way voted against management. 1 filer reported this item without a management mark.
SECTION 14A SAY-ON-PAY VOTESIssuer
Advisory vote on executive pay (say-on-pay)
141 vote records from 84 filers. 11 of the 80 filers that marked the item either way voted against management. 4 filers reported this item without a management mark.
AUDIT-RELATEDIssuer
Audit-related items (auditor ratification)
41 vote records from 25 filers. 0 of the 24 filers that marked the item either way voted against management. 1 filer reported this item without a management mark.
COMPENSATIONIssuer
COMPENSATION: management items
Management items in this category are shown together; filers word and number them differently.
164 vote records from 27 filers. 0 of the 26 filers that marked the item either way voted against management. 1 filer reported this item without a management mark.
OTHERIssuer
OTHER: management items
Management items in this category are shown together; filers word and number them differently.
16 vote records from 5 filers. 0 of the 4 filers that marked the item either way voted against management. 1 filer reported this item without a management mark.
How the largest families voted
| Family | 1. Directors | 2. Say-on-pay | 3. Auditor |
|---|---|---|---|
| Vanguard | For | For | For |
| BlackRock and iShares | No report | For | No report |
| Dimensional | No report | For | No report |
| State Street and SPDR | For | For | For |
| American Century | For | For | For |
| Franklin Templeton | No report | For | No report |
| Nuveen and TIAA | No report | For | No report |
| John Hancock and Manulife | For | For | For |
| J.P. Morgan | Split or no vote | For | Split or no vote |
| Jackson National funds | For | For | For |
| Northern Trust and FlexShares | For | For | For |
| Lincoln Financial | For | For | For |
| Brighthouse Funds | For | For | For |
| BNY Mellon | For | For | For |
| Capital Group and American Funds | No report | For | No report |
| AllianceBernstein | No report | For | No report |
| Macquarie and Delaware Funds | No report | For | No report |
| Janus Henderson | No report | For | No report |
* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.
Questions
How did large funds vote at the Teva Pharmaceutical Industries Limited meeting?
86 Form N-PX filers reported votes at the meeting of 5 Jun 2025. On say-on-pay, 11 of 80 voted against management (13.8%). The family table lists each of the largest families item by item.
Is this the meeting result?
No. These are the votes of funds and managers that file Form N-PX, counted by filer and by the shares they reported. The certified result, which includes every shareholder, is reported by Teva Pharmaceutical Industries Limited on Form 8-K.
Why are director elections shown as counts only?
Director records name the nominee. This site does not publish pages or rows about individuals, so for director elections it keeps the number of nominees and the split of votes and discards the wording.
Every meeting on file for Teva Pharmaceutical Industries Limited
Provenance: SEC EDGAR, Form N-PX and N-PX/A filings listing Teva Pharmaceutical Industries Limited with a meeting date within three days of 5 Jun 2025. Proposal titles are the most common wording among filers and are replaced by the SEC category where a wording could name a person. Not verified by the SEC. Filings read through 23 Sep 2026.